ECSP077299A - Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos - Google Patents

Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos

Info

Publication number
ECSP077299A
ECSP077299A EC2007007299A ECSP077299A ECSP077299A EC SP077299 A ECSP077299 A EC SP077299A EC 2007007299 A EC2007007299 A EC 2007007299A EC SP077299 A ECSP077299 A EC SP077299A EC SP077299 A ECSP077299 A EC SP077299A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
treatment
new pharmaceutical
phenoxi
trifluorometil
Prior art date
Application number
EC2007007299A
Other languages
English (en)
Inventor
Jacques Dumas
Susanne Zuleger
Paul Ehrlich
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ECSP077299A publication Critical patent/ECSP077299A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

La invención se relaciona con nuevas composiciones farmacéuticas que comprenden una dispersión sólida del compuesto de la fórmula (I), procesos para preparar estas nuevas composiciones farmacéuticas y su uso en el tratamiento de trastornos hiperproliferativos, tal como cáncer, ya sea como único agente o en combinación con otras terapias.
EC2007007299A 2004-08-27 2007-03-05 Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos ECSP077299A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60475204P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
ECSP077299A true ECSP077299A (es) 2007-04-26

Family

ID=35517032

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007299A ECSP077299A (es) 2004-08-27 2007-03-05 Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos

Country Status (41)

Country Link
US (2) US20060058358A1 (es)
EP (2) EP2589384A1 (es)
JP (1) JP5017115B2 (es)
KR (1) KR101336737B1 (es)
CN (2) CN102885813A (es)
AR (1) AR050616A1 (es)
AU (1) AU2005279996A1 (es)
BR (1) BRPI0514715B1 (es)
CA (1) CA2578438C (es)
CL (1) CL2010001484A1 (es)
CR (1) CR8980A (es)
CY (1) CY2017038I1 (es)
DK (1) DK1793824T3 (es)
EA (1) EA010832B1 (es)
EC (1) ECSP077299A (es)
ES (1) ES2561618T3 (es)
GT (1) GT200500230A (es)
HN (1) HN2005000484A (es)
HR (1) HRP20160156T1 (es)
HU (2) HUE026654T2 (es)
IL (1) IL181590A (es)
LT (1) LTC1793824I2 (es)
LU (1) LUC00047I2 (es)
MA (1) MA28911B1 (es)
ME (2) ME00152B (es)
MX (1) MX2007002397A (es)
MY (1) MY191349A (es)
NI (1) NI200700064A (es)
NO (2) NO343937B1 (es)
NZ (1) NZ553557A (es)
PE (2) PE20100432A1 (es)
PL (1) PL1793824T3 (es)
PT (1) PT1793824E (es)
RS (1) RS54580B1 (es)
SI (1) SI1793824T1 (es)
TN (1) TNSN07076A1 (es)
TW (1) TWI369987B (es)
UA (1) UA92472C2 (es)
UY (1) UY29086A1 (es)
WO (1) WO2006026500A1 (es)
ZA (1) ZA200702392B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) * 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
KR101381454B1 (ko) * 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
KR101335932B1 (ko) * 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090074917A2 (en) * 2006-07-26 2009-03-19 Remington Direct Lp Low-calorie, no laxation bulking system
US20080026038A1 (en) * 2006-07-26 2008-01-31 Remington Direct Lp No laxation, low flatulence bulking system
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010068951A1 (en) * 2008-12-12 2010-06-17 Fox Chase Cancer Center Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
EP3750526A1 (en) 2010-07-12 2020-12-16 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EA201300420A1 (ru) 2010-10-01 2013-09-30 Байер Интеллектчуал Проперти Гмбх Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN104721142B (zh) * 2013-12-18 2020-04-28 山东新时代药业有限公司 一种利伐沙班固体分散体及其制备方法
US9790185B2 (en) 2014-07-09 2017-10-17 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN111166724A (zh) * 2018-11-09 2020-05-19 北京化工大学 一种瑞戈非尼纳米分散体、片剂及其制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
EP4114359A1 (en) * 2020-03-05 2023-01-11 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN112842998A (zh) * 2021-01-19 2021-05-28 深圳市简一生物科技有限公司 一种瑞戈非尼分散剂及其制备方法
FR3123358B1 (fr) * 2021-05-25 2024-05-10 Vecormat Bfc Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle.
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
CN114767633B (zh) * 2022-04-07 2023-03-31 郑州大学第一附属医院 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4220302A (en) 1978-07-21 1980-09-02 Hampton Diane M Nursing bottle holder
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
EP1449834A3 (en) * 1997-12-22 2004-12-22 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
EP1047418B1 (en) * 1997-12-22 2005-07-27 Bayer Pharmaceuticals Corp. Inhibition of raf kinase using substituted heterocyclic ureas
DE69834842T2 (de) * 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
CZ299125B6 (cs) * 1999-01-13 2008-04-30 Bayer Corporation Difenylové mocoviny substituované omega-karboxyarylovou skupinou jako inhibitory rafkinázy, jejich použití a farmaceutické kompozice s jejich obsahem
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
HUP0300429A2 (hu) * 2000-04-19 2003-07-28 Fujisawa Pharmaceutical Co., Ltd. Javított felszívódási képességű szilárd diszperzió és eljárás az előállítására
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
US20030099703A1 (en) * 2000-08-11 2003-05-29 Shigeru Aoki Drug-containing solid dispersion having improved solubility
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2261643T3 (es) * 2001-02-13 2006-11-16 Astrazeneca Ab Nueva formulacion de liberacion modificada.
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
AU2002365899B2 (en) * 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
US7838541B2 (en) * 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
CA2430180C (en) 2003-05-21 2010-03-16 Royal Group Technologies Limited Cascade shade
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
JP5128948B2 (ja) * 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物

Also Published As

Publication number Publication date
HUS1700047I1 (hu) 2017-12-28
US20060058358A1 (en) 2006-03-16
IL181590A (en) 2013-04-30
TNSN07076A1 (en) 2008-06-02
BRPI0514715A (pt) 2008-06-24
AR050616A1 (es) 2006-11-08
CA2578438A1 (en) 2006-03-09
PE20060505A1 (es) 2006-06-18
HUE026654T2 (en) 2016-07-28
CN102885813A (zh) 2013-01-23
EA010832B1 (ru) 2008-12-30
TWI369987B (en) 2012-08-11
ES2561618T3 (es) 2016-02-29
PL1793824T3 (pl) 2016-06-30
TW200616627A (en) 2006-06-01
MEP35808A (en) 2010-06-10
LUC00047I1 (es) 2017-11-15
HN2005000484A (es) 2010-06-08
PT1793824E (pt) 2016-03-11
KR101336737B1 (ko) 2013-12-04
NO2019033I1 (no) 2019-08-05
IL181590A0 (en) 2007-07-04
HRP20160156T1 (hr) 2016-03-11
JP2008511685A (ja) 2008-04-17
EP1793824B1 (en) 2015-11-18
EP2589384A1 (en) 2013-05-08
NO343937B1 (no) 2019-07-15
MY191349A (en) 2022-06-17
AU2005279996A1 (en) 2006-03-09
EA200700501A1 (ru) 2007-08-31
NO20071584L (no) 2007-05-24
LUC00047I2 (es) 2018-01-10
MA28911B1 (fr) 2007-10-01
LTC1793824I2 (lt) 2017-06-12
EP1793824A1 (en) 2007-06-13
PE20100432A1 (es) 2010-07-21
RS54580B1 (sr) 2016-06-30
CA2578438C (en) 2015-10-06
UA92472C2 (ru) 2010-11-10
GT200500230A (es) 2006-03-28
BRPI0514715B1 (pt) 2021-11-03
CY2017038I2 (el) 2018-06-27
CR8980A (es) 2007-10-22
NI200700064A (es) 2008-03-03
CY2017038I1 (el) 2018-06-27
WO2006026500A1 (en) 2006-03-09
NZ553557A (en) 2010-08-27
DK1793824T3 (en) 2016-02-01
JP5017115B2 (ja) 2012-09-05
CL2010001484A1 (es) 2011-04-25
ZA200702392B (en) 2008-11-26
UY29086A1 (es) 2006-03-31
CN101287463A (zh) 2008-10-15
KR20070067104A (ko) 2007-06-27
MX2007002397A (es) 2007-05-15
ME00152B (me) 2010-10-10
US20170165243A1 (en) 2017-06-15
SI1793824T1 (sl) 2016-03-31

Similar Documents

Publication Publication Date Title
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
CU20130033A7 (es) Imidazopiridazinas sustituidas
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
CR20210108A (es) Benzamidas sustituidas con 1, 3-tiazol-2-ilo
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2020001404A (es) Dihidrooxadiazinonas.
UY31780A (es) Fenoxibenzamidas sustituidas
TW200738659A (en) Novel compounds
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
EA201071369A1 (ru) Композиции для лечения выпадения волос
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.